Page 1

Bactiguard Interim report second quarter 2021 Major progress in the licensing business and several new partnerships for wound care Second quarter 2021 ( April - June ) • • • • Revenues amounted to SEK 46.0 ( 48.2 ) million , a decrease of 5 % . Adjusted for currencies revenues increased 5 % . EBITDA amounted to SEK 1.8 ( 10.5 ) million with an EBITDA margin of 4 % ( 22 % ) . Operating profit amounted to SEK -10.0 ( -0.8 ) million . Net loss for the period amounted to SEK -12.0 ( -0.3 ) million . Earnings per share amounted to SEK -0.36 ( -0.01 ) . Cash flow from operating activities amounted to SEK 5.5 ( 3.6 ) million , corresponding to SEK 0.16 ( 0.11 ) per share . Key events during the second quarter • • • Zimmer Biomet's trauma implants with Bactiguard's infection prevention technology were launched in select EMEA markets and Bactiguard received a first milestone payment of USD 1 million . Bactiguard and schülke entered partnership for wound care in Germany . Agreement signed with Apotek Hjärtat for wound care in Sweden . First half year 2021 ( January - June ) • 9 % . Adjusted for currencies the decrease was 4 % . Revenues amounted to SEK 87.8 ( 96.3 ) million , a decrease of • EBITDA amounted to SEK 3.7 ( 24.9 ) million , with an EBITDA margin of 4 % ( 26 % ) . Operating profit amounted to SEK -19.7 ( 3.1 ) million . • • Net loss for the period amounted to SEK -22.6 ( -11.4 ) million . Earnings per share amounted to SEK -0.68 ( -0.34 ) . Cash flow from operating activities amounted to SEK 4.6 ( 0.1 ) million , corresponding to SEK 0.14 ( 0.00 ) per share . Covid - 19 effects • During the second quarter , we saw a continued stabilization of license revenues from BD as healthcare in the US recovered faster than the rest of the world . The roll - out of vaccines and fewer new infected will gradually have a positive effect on the return to a more normal situation for healthcare . At the same time , the global health care backlog continues to increase and must be managed . In that perspective , we see a great need for infection prevention , which is positive for both the license and BIP businesses . However , near - term developments are still difficult to assess . • The wound care range will be introduced in Spain in collaboration with Farmaban . • The portfolio is broadened to include wound care for pets in collaboration with Musti Group . Key figures Apr - Jun Apr - Jun Jan - Jun Jan - Jun Full Year RTM 2021 2020 2021 2020 2020 2021 Revenues² , SEKM 46.0 48.2 87.8 96.3 186.0 177.5 EBITDA³ , SEKM EBITDA margin³ , % 1.8 10.5 3.7 24.9 26.7 5.5 4 % 22 % 4 % 26 % 14 % 3 % Operating profit² , SEKM -10.0 -0.8 -19.7 3.1 -17.6 -40.4 Net profit / loss for the period² , SEKM -12.0 -0.3 -22.6 -11.4 -38.4 -49.5 Adjusted net profit / loss for the period 1,3 , SEKm -12.0 -2.2 -22.6 -0.6 -27.5 -49.5 Earnings per share² , SEK -0.36 -0.01 -0.67 -0.34 -1.14 -1.48 Adjusted earnings per share 1,3 , SEK -0.36 -0.07 -0.67 -0.02 -0.82 -1.48 Operating cash flow² , SEKM 5.5 3.6 4.6 0.1 0.7 5.2 Operating cash flow per share³ , SEK 0.16 0.11 0.14 0.00 0.02 0.16 Equity ratio³ , % 53 % 57 % 53 % 57 % 55 % 53 % Net debt³ , SEKM 254.3 241.6 254.3 241.6 254.1 254.3 1 The part of the purchase price for the acquisition of Vigilenz that consisted of shares is considered , for accounting purposes , as a financial instrument and the forward effect is thus reported as a financial item in the income statement and has affected net profit / loss for the second quarter 2020 with SEK 1,9 million and full year 2020 with SEK -10.9 million . The adjustment is only affecting accounting and has no effect on cash flow . 2 Defined according to IFRS . 3 Alternative performance measure . For definition and reconciliation , see pages 18-19 BACTIGUARD HOLDING AB ( publ ) Corporate registration number 556822-1187 1